Welcome to our dedicated page for West Pharm Svcs news (Ticker: WST), a resource for investors and traders seeking the latest updates and insights on West Pharm Svcs stock.
West Pharmaceutical Services, Inc. (NYSE: WST) provides injectable drug administration solutions and services for pharmaceutical, biotechnology and generic drug customers. Its business includes elastomer-based packaging components such as stoppers, seals and plungers, nonglass containment technologies, auto-injectors and contract services for device manufacturing, assembly, packaging, validation, analytical testing and regulatory support.
News about West commonly covers quarterly results, revenue guidance, Proprietary Products and Contract Manufacturing performance, capacity additions for high-volume injectable therapies, and demand tied to biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. Other recurring developments include dividends, share repurchase authorizations, investor conference participation and governance or executive-transition updates.
West Pharmaceutical Services (NYSE: WST) has been awarded the Biotech Innovation Award for its DeltaCube™ Modeling Platform at INTERPHEX 2022 in New York. This platform aids in container closure system (CCS) selection, optimizing drug development processes. Senior VP Chris Ryan emphasized its role in reducing risk and accelerating drug delivery to patients. The DeltaCube™ platform leverages over 90 years of experience to enhance vial integrity and troubleshoot defects efficiently. In 2021, West generated $2.83 billion in net sales, underscoring its position in the market.
West Pharmaceutical Services, a leader in injectable drug administration solutions, will participate in INTERPHEX 2022 on May 26, 2022. The company aims to showcase advancements in packaging technology, addressing industry challenges and trends. Notable presentations include a session on Novel Parenteral Packaging Components by experts Simon Cote and Eric Kurtz, highlighting innovations in fill-finish processing. Additionally, the DeltaCube™ Modeling Platform will be featured in a poster session by Anthony Bucci, visualizing component dimensional consistency. West generated $2.83 billion in net sales in 2021.
West Pharmaceutical Services (NYSE: WST) announced significant leadership changes on May 12, 2022. Bernard J. Birkett has been appointed Chief Financial and Operations Officer, expanding his role to include Global Operations and Supply Chain following David Montecalvo's resignation. Cindy Reiss-Clark is now Chief Commercial Officer, while Chris Ryan has been named Senior Vice President for Containment and Glass Systems. Kathy dePadua joins as Vice President and Chief Quality Officer, bringing extensive experience from GE Healthcare. These transitions aim to strengthen West's leadership in injectable drug administration.
West Pharmaceutical Services, a leader in injectable drug administration solutions, will participate in the Bank of America Securities 2022 Healthcare Conference from May 9-13 in Las Vegas, presenting on May 10 at 11:20 AM PDT. Additionally, the company will present at the 42nd Annual William Blair Growth Stock Conference in Chicago on June 6 and at the Jefferies Global Healthcare Conference in New York on June 9. A live audio webcast will be available on their website, with replays for 90 days. West reported $2.83 billion in net sales in fiscal year 2021.
West Pharmaceutical Services, Inc. (WST) reported first-quarter 2022 net sales of $720 million, reflecting a 7.4% increase, with organic growth of 11%. Diluted EPS rose to $2.29, up 15.1%. The company reaffirmed its full-year net sales guidance of $3.050 billion to $3.075 billion and raised adjusted-diluted EPS guidance to $9.30 to $9.45. Additionally, a dividend of $0.18 per share will be paid on August 3, 2022. The Proprietary Products Segment grew 10.6%, while Contract-Manufactured Products saw a 6.6% decline.
West Pharmaceutical Services (NYSE: WST) will release its first-quarter 2022 financial results on April 28, 2022, before market opening. The company will conduct a conference call at 9:00 a.m. Eastern Time to discuss these results and business expectations. Interested participants can dial 877-930-8295 (U.S.) or 253-336-8738 (International) using conference ID 6690124. A live broadcast will be available on West's website, along with a slide presentation. An online archive of the call will be accessible three hours post-event until May 5, 2022.
Pneuma Systems Corporation has partnered with West Pharmaceutical Services (NYSE: WST) to enhance drug therapy patient experiences. This collaboration aims to develop drug delivery solutions utilizing Pneuma's innovative closed-loop fluid flow control platform, with West providing technical and financial support. The intravenous pump market, projected to reach USD 20.5 billion in five years, underscores the significance of this partnership. The collaboration emphasizes improvements in workflow and patient safety, as West integrates PneumaDrive™ technology into various healthcare settings.
West Pharmaceutical Services, Inc. (NYSE: WST) announced that its team members received prestigious awards at the 2022 PDA Annual Meeting in Dallas. Liang Fang and Marissa Rase were honored with the 2021 Fred Simon Award for their paper on excipient-container interactions affecting prefilled syringes. Additionally, Chief Scientific Officer Fran DeGrazio received the 2021 Edward Smith Packaging Science Award for significant contributions to pharmaceutical packaging. West continues to highlight its commitment to innovation and safety in injectable drug administration.
West Pharmaceutical Services (NYSE: WST) will participate in the 2022 PDA Annual Meeting in Exton, Pennsylvania, on April 4-6, 2022. The company plans to showcase advancements in packaging science through keynote presentations, moderated sessions, and scientific posters.
Key highlights include a presentation on a Closed-Loop Wearable Injector System for Naloxone and various poster sessions focusing on vial container closure systems and prefilled syringes. With $2.83 billion in net sales for 2021, West emphasizes its leadership in ensuring quality and stability in injectable drug products.
TYME Technologies, Inc. announces key leadership changes, appointing Christine D. Baker to its Board of Directors. With over 30 years in biotech, her expertise in business development and commercialization will guide the company's cancer therapies. Douglas A. Michels becomes Chairman of the Board, bringing 39 years of healthcare experience. The changes aim to strengthen TYME's position in developing cancer metabolism-based therapies (CMBTs™) and enhance its strategic direction.